David W. Henry

Suggest Changes
Learn More
BACKGROUND The aims of this study were to determine the feasibility of the combination of low dose, anti-angiogenic chemotherapy with standard therapy for patients with metastatic Ewing sarcoma (ES),(More)
Patients with metastatic Ewing sarcoma family of tumors (ES) continue to have a poor outcome with a 3-year event free survival of 20% despite the use of dose-intensified chemotherapy [1–3].(More)
  • 1